home / stock / phio / phio news

PHIO News and Press, Phio Pharmaceuticals Corp. From 11/07/25

Stock Information
Company Name: Phio Pharmaceuticals Corp.
Stock Symbol: PHIO
Market: NASDAQ
Website: phiopharma.com
Menu
PHIO PHIO Quote PHIO Short PHIO News PHIO Articles PHIO Message Board
Get PHIO Alerts

News, Short Squeeze, Breakout and More Instantly...
PHIO - Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its pr...
PHIO - Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL ® siRNA gene silencing technology to eliminate cancer. Phio announced today that...

PHIO - US Companies Moving the Markets, Morning edition
Tue, Nov 04, 2025 as of 10.00 am ET

A look at the top 10 most actives in the United States MSP Recovery Inc. (MSPR) rose 136.6% to $0.5205 on volume of 871,666,816 shares EZGO Technologies Ltd. (EZGO) rose 29.1% to $0.1752 on volume of 233,724,963 shares Kenvue Inc. (KVUE) rose 12.3% to $16.14 on volume of 203,525,996 shares ...

PHIO - US Companies Moving the Markets, Evening edition
Mon, Nov 03, 2025 as of 4:00 pm ET

A look at the top 10 most actives in the United States MSP Recovery Inc. (MSPR) rose 198.4% to $0.6564 on volume of 840,159,216 shares EZGO Technologies Ltd. (EZGO) rose 32.2% to $0.1794 on volume of 227,136,454 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 1.8% to $3.2617 ...
PHIO - Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

King of Prussia, Pennsylvania--(Newsfile Corp. - November 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced the entry int...

PHIO - Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Pathologic Clearance: 100% Tumor Clearance (Complete Response) in One Patient, Greater than 90% (Near Complete Response) in Second Patient, Greater than 50% (Partial Response) in Third Patient Pathologic Results Assessed at Approximately 5 Weeks Safety Monitoring Committee Issues Favor...

PHIO - Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

King of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL ® gene silencing technology to eliminate cancer. Phio is pleased to announ...
PHIO - Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Registration Link Below for September 30, 2025 12 PM EST Presentation and Live Q&A King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietar...

PHIO - Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Key updates to include advances made in the on-going clinical trial for INTASYL siRNA lead product candidate PH-762 King of Prussia, Pennsylvania--(Newsfile Corp. - September 18, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeuti...

PHIO - Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Clinical trial advances to anticipated final cohort for INSTASYL siRNA lead product candidate PH-762 5th cohort patients now being treated in on-going clinical study King of Prussia, Pennsylvania--(Newsfile Corp. - September 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-...
Previous 10 Next 10